IL316016A - Combined treatment for cancer - Google Patents
Combined treatment for cancerInfo
- Publication number
- IL316016A IL316016A IL316016A IL31601624A IL316016A IL 316016 A IL316016 A IL 316016A IL 316016 A IL316016 A IL 316016A IL 31601624 A IL31601624 A IL 31601624A IL 316016 A IL316016 A IL 316016A
- Authority
- IL
- Israel
- Prior art keywords
- combination therapy
- treating cancer
- cancer
- treating
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362612P | 2022-04-07 | 2022-04-07 | |
| PCT/EP2023/059126 WO2023194528A1 (en) | 2022-04-07 | 2023-04-06 | Combination therapy for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316016A true IL316016A (en) | 2024-11-01 |
Family
ID=86185292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316016A IL316016A (en) | 2022-04-07 | 2023-04-06 | Combined treatment for cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250235448A1 (https=) |
| EP (1) | EP4504180A1 (https=) |
| JP (1) | JP2025511401A (https=) |
| KR (1) | KR20240170956A (https=) |
| CN (1) | CN118973572A (https=) |
| AU (1) | AU2023248685A1 (https=) |
| CA (1) | CA3254948A1 (https=) |
| IL (1) | IL316016A (https=) |
| MX (1) | MX2024012368A (https=) |
| TW (1) | TW202404593A (https=) |
| WO (1) | WO2023194528A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026021478A1 (zh) * | 2024-07-23 | 2026-01-29 | 江苏恒瑞医药股份有限公司 | Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0705903B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Mutations in the 17q-linked breast and ovarian cancer susceptibility gene |
| DK0699754T3 (da) | 1994-08-12 | 2001-02-26 | Myriad Genetics Inc | Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
-
2023
- 2023-04-06 WO PCT/EP2023/059126 patent/WO2023194528A1/en not_active Ceased
- 2023-04-06 US US18/853,491 patent/US20250235448A1/en active Pending
- 2023-04-06 AU AU2023248685A patent/AU2023248685A1/en active Pending
- 2023-04-06 KR KR1020247036943A patent/KR20240170956A/ko active Pending
- 2023-04-06 CN CN202380032429.6A patent/CN118973572A/zh active Pending
- 2023-04-06 CA CA3254948A patent/CA3254948A1/en active Pending
- 2023-04-06 JP JP2024559034A patent/JP2025511401A/ja active Pending
- 2023-04-06 EP EP23719307.3A patent/EP4504180A1/en active Pending
- 2023-04-06 IL IL316016A patent/IL316016A/en unknown
- 2023-04-07 TW TW112112999A patent/TW202404593A/zh unknown
-
2024
- 2024-10-04 MX MX2024012368A patent/MX2024012368A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012368A (es) | 2024-11-08 |
| AU2023248685A1 (en) | 2024-11-14 |
| CN118973572A (zh) | 2024-11-15 |
| TW202404593A (zh) | 2024-02-01 |
| US20250235448A1 (en) | 2025-07-24 |
| EP4504180A1 (en) | 2025-02-12 |
| JP2025511401A (ja) | 2025-04-15 |
| KR20240170956A (ko) | 2024-12-05 |
| CA3254948A1 (en) | 2023-10-12 |
| WO2023194528A1 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304275A (en) | Cancer treatment methods | |
| PT4225297T (pt) | Terapia de combinação para o tratamento de cancro | |
| IL307964A (en) | Combined treatment for cancer | |
| IL320332A (en) | Cancer treatment methods | |
| ZA202310076B (en) | Combination therapies for treating cancer | |
| IL319513A (en) | Compounds for cancer treatment | |
| IL316016A (en) | Combined treatment for cancer | |
| IL316017A (en) | Combined treatment for cancer | |
| GB202301902D0 (en) | Combination therapy for cancer | |
| IL288178A (en) | Combined gmci and ddri treatment for cancer | |
| GB202218395D0 (en) | Cancer therapy | |
| IL317573A (en) | Combination therapy for cancer treatment | |
| IL316019A (en) | Combined treatment for cancer | |
| IL305777A (en) | Medical combination for cancer treatment | |
| IL326216A (en) | Combination therapy for prostate cancer | |
| CA3272243A1 (en) | Combination therapy for treating cancer | |
| HK40121856A (en) | Combination therapy for treating cancer | |
| HK40121918A (en) | Combination therapy for treating cancer | |
| GB202208893D0 (en) | Combination therapy for cancer | |
| IL317472A (en) | Arbecycline for cancer treatment | |
| HK40107047A (en) | Therapeutic combination for treating cancer | |
| IL320482A (en) | Combination therapy for cancer treatment | |
| GB202508616D0 (en) | Combination therapy for cancer | |
| CA3302004A1 (en) | Combination therapy for treating prostate cancer | |
| CA3307092A1 (en) | Combination therapy for cancer treatment |